Suppliers and packagers for generic pharmaceutical drug: TECHNETIUM TC-99M EXAMETAZIME KIT

TECHNETIUM TC-99M EXAMETAZIME KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ge Healthcare	CERETEC	technetium tc-99m exametazime kit	INJECTABLE;INJECTION	019829	NDA	Medi-Physics Inc. dba GE Healthcare.	17156-022-05	5 VIAL in 1 TRAY (17156-022-05) / 5 mL in 1 VIAL	1988-12-30
Ge Healthcare	CERETEC	technetium tc-99m exametazime kit	INJECTABLE;INJECTION	019829	NDA	Medi-Physics, Inc. dba GE Healthcare	17156-025-05	1 KIT in 1 CARTON (17156-025-05) * 5 mL in 1 VIAL, GLASS (17156-022-05) * 2.5 mL in 1 VIAL, GLASS (17156-027-01)	2018-09-25
Jubilant	DRAX EXAMETAZIME	technetium tc-99m exametazime kit	POWDER;INTRAVENOUS	208870	NDA	Jubilant DraxImage Inc., dba Jubilant Radiopharma	65174-200-05	5 VIAL in 1 CARTON (65174-200-05) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (65174-200-01)	2017-08-17

Technetium Tc-99m Exametazime Kit Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for Technetium Tc-99m Exametazime (Tc-99m HMPAO) kits, a radiopharmaceutical used in diagnostic imaging. Key suppliers, regulatory considerations, and market dynamics are examined to inform R&D and investment decisions.

Who are the Primary Manufacturers of Tc-99m HMPAO Kits?

The production of Tc-99m HMPAO kits is concentrated among a limited number of specialized radiopharmaceutical manufacturers. These companies possess the expertise and infrastructure to handle radioactive materials and ensure product sterility and efficacy.

The primary manufacturers include:

• GE Healthcare: A significant global player in nuclear medicine, GE Healthcare offers Tc-99m HMPAO kits under its Ceretec® brand.
• Curium: Formerly part of Mallinckrodt Pharmaceuticals, Curium is another established supplier of radiopharmaceuticals, including Tc-99m HMPAO.
• Nordion (a Sotera Health company): While Nordion historically played a role in the technetium supply chain, its current direct involvement in HMPAO kit manufacturing requires specific verification against their current product portfolio. Sotera Health's broader focus is on sterilization and health sciences.

These manufacturers operate within a highly regulated environment, subject to stringent oversight by national health authorities.

What is the Regulatory Landscape Governing Tc-99m HMPAO Kit Production and Distribution?

The production, quality control, and distribution of radiopharmaceuticals like Tc-99m HMPAO kits are subject to comprehensive regulatory frameworks globally. These regulations ensure patient safety, product efficacy, and environmental protection.

Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): In the United States, Tc-99m HMPAO kits are regulated as drugs. Manufacturers must comply with Current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Part 210 and 211. Product approval requires submission of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Specific guidance related to radiopharmaceuticals is also relevant.
• European Medicines Agency (EMA): In the European Union, medicinal products, including radiopharmaceuticals, are authorized centrally by the EMA or at the national level by member state competent authorities. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory.
• National Regulatory Authorities: Other countries have their own regulatory agencies (e.g., Health Canada, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, the Therapeutic Goods Administration (TGA) in Australia) that set standards for drug approval, manufacturing, and distribution. These often align with international standards but may have specific national requirements.

Regulatory requirements cover:

• Manufacturing Controls: Strict adherence to cGMP/GMP for drug product manufacturing, including facility design, equipment validation, process validation, personnel training, and quality control testing.
• Quality Control: Rigorous testing of raw materials, in-process samples, and finished products for identity, purity, strength, and sterility. Specific tests for Tc-99m HMPAO include radionuclidic purity, radiochemical purity, and assay.
• Packaging and Labeling: Requirements for secure packaging that maintains sterility and shields from radiation, as well as accurate labeling that includes crucial information such as expiry date, storage conditions, and radioactivity content.
• Distribution: Regulations governing the safe and secure transportation of radioactive materials, often requiring specialized carriers and handling procedures to maintain product integrity and public safety.

What are the Critical Raw Materials and Their Supply Chain Vulnerabilities?

The synthesis of Tc-99m HMPAO kits relies on several critical components, the supply of which can present vulnerabilities.

Critical raw materials include:

• Exametazime (HMPAO): The active pharmaceutical ingredient (API) itself. Its synthesis is a specialized chemical process, and its availability is linked to the manufacturers producing this specific ligand.
• Sodium Pertechnetate (Na[99mTcO4]): This is the source of the radioactive technetium-99m isotope. It is eluted from a molybdenum-99 (Mo-99) generator. The supply of Mo-99 is a significant global concern due to its limited production sites and reliance on aging nuclear reactors.
• Other Reagents: Various buffers, stabilizers, and sterile water for injection (WFI) are also essential. The quality and sterility of these components are paramount.

Supply chain vulnerabilities:

• Molybdenum-99 (Mo-99) Production Disruptions: Mo-99 is primarily produced in a few nuclear reactors worldwide. Extended shutdowns, maintenance, or geopolitical events affecting these reactors can lead to critical shortages of Mo-99 and, consequently, Tc-99m. This directly impacts the availability of all Tc-99m-based radiopharmaceuticals, including HMPAO kits. For example, planned and unplanned outages at major Mo-99 production facilities have historically caused global supply constraints.
• API Manufacturing Capacity: While HMPAO is a specific chemical entity, the number of manufacturers capable of producing it to pharmaceutical standards may be limited. Any disruption at these API manufacturing sites could impact kit production.
• Sterility and Quality Assurance: Maintaining sterility throughout the manufacturing and packaging process is critical. Any breach in aseptic techniques or quality control failures can lead to product recalls, impacting supply and patient access.
• Transportation and Logistics: The specialized handling and rapid delivery required for short-lived radiopharmaceuticals present logistical challenges. Delays in transportation, especially for time-sensitive Tc-99m products, can render batches unusable.

What are the Major Market Trends and Future Outlook for Tc-99m HMPAO Kits?

The market for Tc-99m HMPAO kits is influenced by several factors, including diagnostic imaging trends, competition from alternative imaging modalities, and the persistent Mo-99 supply chain issues.

Major market trends:

• Diagnostic Imaging Demand: Tc-99m HMPAO is primarily used for brain perfusion imaging to evaluate conditions like stroke, dementia, and seizures. Demand is driven by the prevalence of these neurological disorders and the adoption of nuclear medicine diagnostics.
• Technological Advancements: While Tc-99m HMPAO remains a workhorse, advancements in other imaging techniques, such as Positron Emission Tomography (PET) with newer radiotracers, offer increased sensitivity and specificity for certain neurological conditions. This presents a competitive pressure.
• Mo-99 Supply Chain Resilience Efforts: Ongoing global initiatives are focused on diversifying Mo-99 production methods (e.g., non-reactor-based production) and improving supply chain reliability to mitigate the impact of reactor outages. The success of these initiatives will significantly influence the long-term stability of Tc-99m HMPAO supply.
• Regional Market Dynamics: Demand and regulatory approvals can vary by region, influencing market growth and supplier presence. Emerging economies with increasing healthcare infrastructure may represent growth opportunities.

Future outlook:

The outlook for Tc-99m HMPAO kits is one of continued relevance for specific diagnostic applications, albeit within a context of supply chain challenges and evolving diagnostic technologies.

• Stable but Competitive Demand: For established indications like stroke and dementia assessment, Tc-99m HMPAO will likely maintain a stable demand base due to its established clinical utility and cost-effectiveness compared to some PET tracers.
• Mitigation of Supply Shocks: Efforts to secure a more robust Mo-99 supply are critical. Should these efforts prove successful, the supply chain volatility may decrease, stabilizing HMPAO availability.
• Integration with Other Modalities: Tc-99m HMPAO imaging may be increasingly used in conjunction with other imaging modalities (e.g., MRI, CT) for a comprehensive diagnostic picture.
• Limited New Entrants: The high regulatory barriers, specialized manufacturing requirements, and the reliance on a volatile isotope supply make it unlikely that many new manufacturers will enter the Tc-99m HMPAO kit market in the near future.

What are the Key Considerations for Sourcing Tc-99m HMPAO Kits?

Sourcing Tc-99m HMPAO kits requires a strategic approach that prioritizes reliability, quality, and regulatory compliance.

Key sourcing considerations:

• Supplier Reliability and Track Record: Evaluate potential suppliers based on their history of consistent product delivery, quality assurance, and responsiveness to supply chain disruptions.
• Regulatory Compliance: Ensure that all potential suppliers hold the necessary regulatory approvals in your target markets and adhere to cGMP/GMP standards.
• Supply Chain Transparency: Understand the supplier's sourcing of Mo-99 and their contingency plans for supply disruptions.
• Product Quality and Specifications: Verify that the kits meet all required specifications, including radiochemical purity, radionuclidic purity, and stability.
• Logistical Capabilities: Assess the supplier's ability to deliver the time-sensitive radiopharmaceutical product reliably to your facility or distribution points.
• Contractual Agreements: Establish clear contractual terms that address supply volumes, pricing, quality standards, and provisions for supply interruptions.

Key Takeaways

The supply chain for Technetium Tc-99m Exametazime (Tc-99m HMPAO) kits is characterized by a concentrated group of specialized manufacturers operating under stringent regulatory oversight. The primary vulnerabilities lie in the upstream supply of molybdenum-99 (Mo-99), the radioactive isotope precursor, which is susceptible to disruptions from nuclear reactor operations. While demand for Tc-99m HMPAO in neurological diagnostics remains stable, competitive pressures from advanced imaging modalities exist. Sourcing decisions must prioritize supplier reliability, robust regulatory compliance, and an understanding of Mo-99 supply chain dynamics.

FAQs

1. What are the main diagnostic applications for Tc-99m HMPAO kits? Tc-99m HMPAO kits are primarily used for SPECT (Single-Photon Emission Computed Tomography) imaging of brain perfusion. This diagnostic application helps in the evaluation of conditions such as stroke, dementia (e.g., Alzheimer's disease), epilepsy, and other neurological disorders by visualizing blood flow in the brain.

2. How does the global shortage of Molybdenum-99 (Mo-99) affect Tc-99m HMPAO kit availability? Mo-99 is the direct parent isotope of Technetium-99m (Tc-99m), the radioactive component essential for Tc-99m HMPAO kits. Disruptions in Mo-99 production, which typically originates from a few aging nuclear reactors, directly limit the availability of Tc-99m. This scarcity consequently reduces the supply of all Tc-99m-labeled radiopharmaceuticals, including HMPAO kits, leading to potential shortages and delays in diagnostic procedures.

3. Are there alternative radiopharmaceuticals or imaging modalities that can replace Tc-99m HMPAO for brain perfusion imaging? Yes, alternative imaging modalities exist. Positron Emission Tomography (PET) with specific radiotracers (e.g., 18F-FDG for metabolic activity, 18F-Amyloid tracers for plaque detection) offers higher sensitivity and specificity for certain neurological applications. However, Tc-99m HMPAO remains a cost-effective option for assessing regional cerebral blood flow and is widely available where Mo-99 supply is stable.

4. What are the typical shelf-life and handling requirements for Tc-99m HMPAO kits? Tc-99m HMPAO kits are sterile, lyophilized preparations that are reconstituted with Tc-99m pertechnetate immediately before administration. The Tc-99m isotope has a short half-life of approximately 6 hours, meaning the radiopharmaceutical has a very limited usable shelf-life once eluted and prepared. Kits themselves have a defined expiry date, typically several months, but their utility is dictated by the short half-life of the technetium. Strict aseptic techniques and radiation safety protocols are mandatory during reconstitution and handling.

5. What are the implications of the Mo-99 supply chain diversification efforts on the future of Tc-99m HMPAO kit supply? Diversification of Mo-99 production, including exploring non-reactor-based methods, aims to create a more robust and less volatile supply chain. Successful implementation of these alternative production technologies could significantly reduce the frequency and severity of shortages. This would lead to more predictable availability of Tc-99m, thereby stabilizing the supply of Tc-99m HMPAO kits and ensuring consistent access for diagnostic imaging.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/manufacturing-quality-safety/good-manufacturing-practice [3] GE Healthcare. (n.d.). Ceretec® (Technetium Tc 99m Exametazime Kit). Product information is typically available through healthcare professional portals or direct inquiry. [4] Curium. (n.d.). Product Offerings. Information typically available through their corporate website or sales representatives. [5] World Nuclear Association. (n.d.). Molybdenum-99. Retrieved from https://www.world-nuclear.org/get-involved/nuclear-science-and-education/nuclear-reactors-in-the-world/molybdenum-99.aspx